In yesterday’s Wall Street session, Altamira Therapeutics Ltd (NASDAQ:CYTO) shares traded at $0.11, down -11.25% from the previous session.
As of this writing, 1 analysts cover Altamira Therapeutics Ltd (NASDAQ:CYTO). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $286.10 and a low of $286.10, we find $286.10. Given the previous closing price of $0.12, this indicates a potential upside of 238316.67 percent. CYTO stock price is now -53.06% away from the 50-day moving average and -88.59% away from the 200-day moving average. The market capitalization of the company currently stands at $0.94M.
There are 0 analysts who have given it a hold rating, whereas 1 have given it a buy rating. Brokers who have rated the stock have averaged $286.10 as their price target over the next twelve months.
A total of 0.59% of the company’s stock is owned by insiders.
Friday morning saw Altamira Therapeutics Ltd (NASDAQ: CYTO) opened at $0.1319. During the past 12 months, Altamira Therapeutics Ltd has had a low of $0.11 and a high of $6.31. The fifty day moving average price for CYTO is $0.2219 and a two-hundred day moving average price translates $0.9179 for the stock.
The latest earnings results from Altamira Therapeutics Ltd (NASDAQ: CYTO) was released for Jun, 2023. For the current quarter, analysts expect CYTO to generate $59.1M in revenue.
Altamira Therapeutics Ltd(CYTO) Company Profile
Altamira Therapeutics Ltd., a clinical-and commercial-stage biopharmaceutical company, engages in the development of therapeutics that address various unmet medical needs in Switzerland, the United States, Europe, and Australia. The company develops OligoPhore/SemaPhore, a platform for delivery of oligonucleotides, such as small interfering ribonucleic acid or messenger RNA into target cells. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; AM-125 that is in phase II clinical trial for the treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is headquartered in Hamilton, Bermuda.